INIS
patients
100%
natural killer cells
65%
cancer
45%
stem cells
40%
tumors
37%
humans
35%
doses
29%
therapy
26%
antibodies
26%
refractories
23%
receptors
22%
toxicity
20%
maintenance
19%
induction
19%
antigens
18%
dexamethasone
18%
breasts
17%
diseases
17%
levels
16%
safety
15%
in vitro
13%
comparative evaluations
12%
dendrites
12%
prednisone
11%
kidneys
11%
ascorbic acid
11%
interactions
11%
blood
10%
cyclophosphamide
10%
malignancies
10%
Keyphrases
Natural Killer Cells
71%
Multiple Myeloma
34%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Bortezomib
22%
Lenalidomide
21%
Relapsed or Refractory multiple Myeloma
20%
Multiple Myeloma Patients
15%
Daratumumab
14%
Thalidomide
14%
Phase II Study
13%
Myeloma
12%
Natural Killer
12%
Ascorbic Acid
11%
Haploidentical Transplantation
11%
Progression-free Survival
11%
Mucin 1 (MUC1)
11%
NKG2A
10%
Tumor Microenvironment
10%
Hazard Ratio
10%
Killer Cell Immunoglobulin-like Receptor
10%
High-dose Melphalan
10%
Stem Cell Transplantation
9%
Monoclonal Antibody
9%
Newly Diagnosed multiple Myeloma
9%
Alloreactive
8%
Vitamin C
8%
Low-dose Cyclophosphamide
8%
Dendritic Cells
8%
Newly Diagnosed
7%
Surface Imprinted Polymer
7%
Immunology and Microbiology
Natural Killer Cell
65%
Multiple Myeloma
54%
Lenalidomide
18%
Dexamethasone
16%
Daratumumab
14%
Dendritic Cell
14%
Drug Megadose
14%
Human Leukocyte Antigen
13%
T Cell
12%
Cyclophosphamide
12%
Ascorbic Acid
11%
Antibody-Dependent Cell-Mediated Cytotoxicity
11%
Autologous Stem Cell Transplantation
11%
Cytotoxicity
10%
Killer-Cell Immunoglobulin-Like Receptor
10%
Thalidomide
10%
Arm
9%
Low Drug Dose
9%
Progression Free Survival
9%
Monoclonal Antibody
9%
Prednisone
9%
Vitamin C
8%
Lymphocyte
8%
Stem Cell Transplantation
7%
Overall Survival
6%
Immunotherapy
6%
Pomalidomide
5%
Kidney Transplantation
5%
Mucin
5%
Allogeneic Hematopoietic Stem Cell Transplantation
5%